Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases

Author(s): Janice Giasson, Guo Hua Li, Yu Chen

Journal Name: Inflammation & Allergy - Drug Targets (Discontinued)
(Formerly Current Drug Targets - Inflammation & Allergy)

Volume 10 , Issue 4 , 2011


Neutrophil gelatinase-associated lipocalin, or NGAL, an acute phase protein, is part of the lipocalin family. NGAL is highly induced in inflammatory conditions and ischemia, and is a critical component of innate immunity to bacterial infection. Recently, NGAL has been proven as an emerging biomarker for predicting acute kidney injury (AKI). Meanwhile, numerous studies have also demonstrated that NGAL may be a potential biomarker for the diagnosis, prediction, prevention, and prognosis of non-AKI diseases such as chronic kidney diseases, vascular disorders, cancer, preeclampsia, and allergies. This article systematically reviews the clinical utilities of NGAL as a new biomarker for non - AKI diseases.

Keywords: NGAL, biomarker, non-AKI diseases, diagnosis, Acute kidney injury, Anti-neutrophilic cytoplasmic auto-antibodies, Chronic kidney disease, Cardiovascular Disorders, Neutrophil Gelatinase-Associated Lipocalin, vascular disorders, preeclampsia

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [272 - 282]
Pages: 11
DOI: 10.2174/187152811796117753
Price: $58

Article Metrics

PDF: 10